Overview

A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Status:
Completed

Trial end date:
2007-01-25

Target enrollment:

Participant gender:

Summary

This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation [CD] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to respond to, have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, and psoralen and ultraviolet A phototherapy (PUVA).

Phase:

Phase 4

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Antibodies
Antibodies, Monoclonal